Hormonal and biochemical features of alloxan and streptozotocin-induced models of experimental diabetes
Author Affiliations1Scientific Centre of Clinical and Experimental Medicine of SB RAMS 630117, Novosibirsk, Timakov str., 2
2Scientific Centre of Clinical and Experimental Medicine of SB RAMS 630117, Novosibirsk, Timakov str., 2
3Scientific Centre of Clinical and Experimental Medicine of SB RAMS 630117, Novosibirsk, Timakov str., 2
4Scientific Center of Clinical and Experimental Medicine SB RAMS 630117, Novosibirsk, Timakov str., 2
Abstract
The diabetic uremic syndrome with death within the first five days after drug administration has been revealed in 31 % of animals after administration to male Wistar rats diabetogenic dose of alloxan (170 mg / kg body weight); 45 % of the animals demonstrated high sensitivity and 34 % - low sensitivity to diabetogenic action of the drug. The animal deaths have not been observed after administration to rats diabetogenic dose of streptozotocin (50 mg/kg body weight); 55 % of the animals demonstrated high sensitivity and 45 % - low sensitivity to the diabetogenic effects of the drug. Highly-sensitive to the action of alloxan or streptozotocin rats, despite the different mechanisms of injury insular apparatus of the pancreas are similar by intensity of the changes of hormonal and biochemical parameters in 14-21 days after drug administration and can be effectively used to study the effects of hypoinsulinemia and correction of hyperglycemia with various drugs.
Key words
References1. Baranov V.G., Sokoloverova I.M., Gasparyan E.G. et al. Experimental diabetes. Role in clinical diabetology. Leningrad: Nauka, 1983. 240 p. (in Russian)
2. Dreval' A.V., Sadykova R.E., Mazo V.K. Effect of dietary imbalance on the induction and during alloxan diabetes rats // Problemy endokrinologii. 1991. 37. (6). 56-58. (in Russian)
3. Zakir'yanov A.R., Plakhotnii M.A., Onishchenko N.A. et al. Complications of diabetes in rats in the long term modeling of diabetes type 1 // Patologicheskaya fiziologiya i eksperimental'naya terapiya. 2007. (4). 21-25. (in Russian)
4. Kendysh I.N. Regulation of carbohydrate metabolism. Moscow: Meditsina, 1985. 272 p. (in Russian)
5. Obukhova L.A., Druzhinina Yu.G., Pal'chikova N.A. et al. Effect of long-term use of probiotic on morphology and function of the endocrine part of the pancreas in experimental animals with alloxan diabetes // Byulleten' Sibirskogo otdeleniya Rossiyskoy akademii meditsinskikh nauk. 2006. (2). 171-175. (in Russian).
6. Pal'chikova N.A., Kuz'minova O.I., Selyatitskaya V.G. Influence perftoran sensitivity of animals to diabetogenic action of alloxan and the course of experimental diabetes // Byulleten' Sibirskogo otdeleniya Rossiyskoy akademii meditsinskikh nauk. 2006. (3). 113-116. (in Russian)
7. Pal'chikova N.A, Lutov Yu.V., Obukhova L.A., Selyatitskaya V.G. Features of current experimental diabetes when administered in the diet of the animals natural inulin complex // Byulleten' Sibirskogo otdeleniya Rossiyskoy akademii meditsinskikh nauk. 2007. (2). 114-118. (in Russian)
8. Pal'chikova N.A., Selyatitskaya V.G, Shorin Yu.P. Quantitative evaluation of the sensitivity of the experimental animals to diabetogenic action of alloxan // Problemy endokrinologii. 1987. 33. (4). 65-68. (in Russian)
9. Selyatitskaya V.G., Pal'chikova N.A., Kuznetsova N.V. et al. Adrenocortical system activity in alloxan-resistant and alloxan-susceptible rats // Fundamental'nye issledovaniya. 2011. (3). 142-148. (in Russian)
10. Smirnov L.D., Inchina V.I., Kostin Ya.V. et al. Possibility of pharmacological correction of metabolic disorders in experimental diabetes drugs such as antioxidant action // Biomeditsinskaya khimiya. 2004. 50. (3). 502-508. (in Russian)
11. Baydas B., Karagoz S., Meral I. Effects of oral zinc and magnesium supplementation on serum thyroid hormone and lipid levels in experimentally induced diabetic rats // Biol. Trace Elem. Res. 2002. 88. (3). 247-253.
12. Behr G.A., da Silvaa E.G., Romanelli A. et al. Pancreas b-cells morphology, liver antioxidant enzymes and liver oxidative parameters in alloxan-resistant and alloxan-susceptible Wistar rats: a viable model system for the study of concepts into reactive oxygen species // Fundam. Clin. Pharmacol. 2008. 22. 657-666.
13. Briede J., Stivrina M., Stoldere Dz. et al. Effect of cerebrocrast, a new long-acting compound on blood glucose and insulin levels in rats when administered before and after STZ-induced diabetes mellitus // Cell Biochem. Funct. 2007. 25. (6). 673-680.
14. Chatzigeorgiou A., Halapas A., Kalafatakis K., Kamper E. The use of animal models in the study of diabetes mellitus // In Vivo. 2009. 23. (2). 245-258.
15. Celik S., Erdogan S., Tuzcu M. Caffeic acid phenethyl ester (CAPE) exhibits significant potential as an antidiabetic and liver-protective agent in streptozotocin-induced diabetic rats // Pharmacol. Res. 2009. 60. (4). 270-276.
16. Chan O., Inouye K., Vranic M. et al. Hyperactivation of the hypothalamo-pituitary-adrenocortical axis in streptozotocin-diabetes is associated with reduced stress responsiveness and decreased pituitary and adrenal sensitivity // Endocrinology. 2002. 143. (5). 1761-1768.
17. Elsner M., Tiedge M., Guldbakke B. et al. Importance of the GLUT2 glucose transporter for pancreatic beta cell toxicity of alloxan // Diabetologia. 2002. 45. (11). 1542-1549.
18. Evan A.P., Mong S.A., Connors B.A. et al. The effect of alloxan, and alloxan-induced diabetes on the kidney // Anat. Rec. 1984. 208. (1). 33-47.
19. Evan A.P., Mong S.A., Connors B.A. et al. The effect of streptozotocin and streptozotocin-induced diabetes on the kidney // Ren. Physiol. 1984. 7. (2). 78-89.
20. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes // Diabetologia. 2008. 51. 216 - 226.
21. Mathews C.E., Leite E.H. Constitutive diffe_rences in antioxidant defense status distinguish alloxan-resistant and alloxan-susceptible mice // Free Radic. Biol. Med. 1999. 27. (3-4). 449-455.
22. Schein P.S., Loftus S. Streptozotocin: Depression of mouse liver pyridine nucleotides // Cancer Res. 1968. 28. 1501-1506.
23. Selyatitskaya V.G., Cherkasova O.P., Pankina T.V., Palchikova N.A. Functional state of adrenocortical system in rats with manifest alloxan-induced diabetes mellitus // Bull. Exp. Biol. Med. 2008. 146. (6). 708-710.
24. Selyatitskaya V.G., Palchikova N.A., Kuznetsova N.V. Adrenocortical system activity in alloxan-resistant and alloxan-susceptible Wistar rats // J. Diabetes Mellit. 2012. 2. (2). 165-169.
25. Shkurupiy V.A, Palchikova N.A., Selyatitskaya V.G. et al. Silica inflammation modulate lipoperoxide and thiobarbituric acid reactive sybstances levels in liver and glucose concentration in blood of alloxan diabetic rats // Mod. Res. Inflamm. 2012. 1. (2). 19-25.
26. Szkudelski T., Kandulska K., Okulicz M. Alloxan in vivo does not only exert deleterious effects on pancreatic B cells // Physiol. Res. 1998. 47. (5). 343-346.
27. Szkudelski T. The Mechanism of alloxan and streptozotocin action in B cells of the rat pancreas // Ibed. 2001. 50. (6). 536-546.
28. Tanaka K., Nanbara S., Tanaka T. et al. Aminotransferase activity in the liver of diabetic mice // Diabetes Res. Clin. Pract. 1988. 5. (1). 71-75.
29. Tavangar K., Murata Y., Pedersen M.E. et al. Regulation of lipoprotein lipase in the diabetic rat // J. Clin. Invest. 1992. 90. (5). 1672-1678.
About Authors (Correspondence):
Palchikova N.A. - doctor of biological sciences, leading researcher, е-mail: labend@mail.ru
Kuznetsova N.V. - researcher, е-mail: labend@soramn.ru
Kuzminova O.I. - candidate of medical sciences, senior researcher, е-mail: labend@soramn.ru
Selyatitskaya V.G. - doctor of biological sciences, professor, head of the laboratory, е-mail: ccem@soramn.ru
Full Text